This is what CTIX told us months ago...

Cellceutix formed a collaborative agreement with Beth Israel Deaconess Medical Center for combination studies with multikinase inhibitors, under development from a large pharmaceutical manufacturer, which activate pro-apoptotic activity by translocation of p53 in mitochondria and inducing apoptosis. This study will provide vital insight to exploit the nuclear and/or mitochondrial pro-apoptotic function by Kevetrin in combination with other multikinase inhibitors in treatment of these malignancies.